Mosaic ImmunoEngineering (CPMV) Operating Income (2010 - 2026)
Mosaic ImmunoEngineering (CPMV) posted Operating Income of -$154802.0 for Q1 2026, down 4.5% on a QoQ basis from -$148133.0 in Q4 2025, and up 11.43% year-over-year from -$138926.4 in Q1 2025.
Powered by 
Analysis
Mosaic ImmunoEngineering (CPMV) Operating Income (2010 - 2026) Analysis & Trends
Mosaic ImmunoEngineering has reported Operating Income for 8 years, with the latest figure at -$154802.0 in Q1 2026.
- On a quarterly basis, Operating Income rose 11.43% year-over-year to -$154802.0 in Q1 2026; TTM through Mar 2026 was -$596147.0, a 24.12% increase from a year earlier, with the FY2025 full-year figure at -$616119.0, up 29.96% from the prior year.
- Operating Income was -$154802.0 for Q1 2026 at Mosaic ImmunoEngineering, down from -$148133.0 in the prior quarter.
- The five-year high for Operating Income was -$144358.0 in Q3 2025, with the low at -$883726.0 in Q2 2022.
- Average Operating Income over 5 years is -$333992.1, with a median of -$274302.0 recorded in 2024.
- The sharpest annual moves came in 2023 and 2025: Operating Income soared 60.11% in 2023, then gained 1.35% in 2025.
- Over 5 years, Operating Income stood at -$497554.0 in 2022, then jumped by 44.61% to -$275618.0 in 2023, then soared by 45.52% to -$150157.0 in 2024, then gained by 1.35% to -$148133.0 in 2025, then retreated by 4.5% to -$154802.0 in 2026.
- The last three Operating Income figures came in at -$154802.0 (Q1 2026), -$148133.0 (Q4 2025), and -$144358.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Mosaic ImmunoEngineering | 434,528.21 | 434,528.21 | - | -154,802.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -154,802.00 |
| Dec 31, 2025 | -148,133.00 |
| Sep 30, 2025 | -144,358.00 |
| Jun 30, 2025 | -148,854.00 |
| Mar 31, 2025 | -174,774.00 |
| Dec 31, 2024 | -150,157.00 |
| Sep 30, 2024 | -186,430.00 |
| Jun 30, 2024 | -274,302.00 |
| Mar 31, 2024 | -268,766.00 |
| Dec 31, 2023 | -275,618.00 |
| Sep 30, 2023 | -311,871.00 |
| Jun 30, 2023 | -352,506.00 |
| Mar 31, 2023 | -459,773.00 |
| Dec 31, 2022 | -497,554.00 |
| Sep 30, 2022 | -517,206.00 |
| Jun 30, 2022 | -883,726.00 |
| Mar 31, 2022 | -729,036.00 |
| Dec 31, 2021 | -824,959.00 |
| Sep 30, 2021 | -961,057.00 |
| Nov 30, 2011 | -781,296.00 |